Our Financial Performance
-
Aug 31, 2022Accounts for the Half-Year ended on June 30, 2022
Investor Resources
-
May 18, 2023Notice of Election of DirectorsMay 18, 2023Ballot paper for voting through postMay 3, 2023Notice of Annual General MeetingMay 3, 2023Operational and Financial HighlightsMay 3, 2023Pattern of shareholding as at December 31, 2022May 3, 2023Proxy Form
Investor Resources
-
PDFMedia
Archives of Financial Accounts
-
For Investors Complaints Only
For complaints and queries, please contact
Muhammad AbuBakar Siddiq
Company SecretaryEmail: company.secretary@sanofi.com
Phone: +92 21 35060221-35DISCLAIMER: “In case your complaint has not been properly redressed by us, you may lodge your complaint with Securities and Exchange Commission of Pakistan (the “SECP”). However, please note that SECP will entertain only those complaints which were at first directly requested to be redressed by the Company and the Company has failed to redress the same. Further, the complaints that are not relevant to SECP’s regulatory domain/competence shall not be entertained by the SECP.
This website was last updated on December 2021
We are pleased to announce that the Share Purchase Agreement announced in May 2022 has concluded successfully. Following completion of all legal, regulatory, and statutory obligations, all shares held by Sanofi in Sanofi-aventis Pakistan Limited have been transferred to an investor consortium led by Packages Limited.
We will continue local manufacture, along with the import of some products, as before, and our teams will continue to focus on delivering our quality medicines and vaccines to the patients of Pakistan.
We are now a Packages Group Company with a rich legacy of excellence and reliability, addressing the full spectrum of healthcare needs, from wellness to prevention to management, treatment and cure.
We will reveal our new brand identity in the future, so stay tuned!
